Reneuron (AIM: RENE.L) is a UK based Proprietary Stem Cell based Exosome Technologies company. Its primary objective is the development of novel stem cell based technologies targeting areas of significant unmet or poorly met medical need.
Research
8 Nov 2023 Interims H1 2023 & New data presented
ReNeuron Group Plc
4 Sep 2023 Update – Closer To Exosome Validation
ReNeuron Group Plc
25 May 2023 Prelims: The Path To Exosome Platform Validation
ReNeuron Group Plc
19 Jan 2023 Update: Laser-like focus on CustomEx™
ReNeuron Group Plc
6 Dec 2022 Interims: Considerable commercial potential
ReNeuron Group Plc
7 Oct 2022 Update: Exosome Platform Profile Improves
ReNeuron Group Plc
21 Sep 2022 Update: All-in on Exosomes
ReNeuron Group Plc
7 Jul 2022 Prelims: Funding the advanced drug delivery platform
ReNeuron Group Plc
20 Jan 2022 Update – Exosomes become sole focus
ReNeuron Group Plc
10 Dec 2021 Interims – Exosomes float into focus in H1 FY21 results
ReNeuron Group Plc
22 Oct 2021 Update
ReNeuron Group Plc
29 Apr 2021 Initiation – Advancing the regenerative potential of stem cells
ReNeuron Group Plc
8 Apr 2021 Prelims – hRPC study confirmed back on track
ReNeuron Group Plc
